Design Therapeutics Stock Market Value
| DSGN Stock | USD 5.53 0.05 0.91% |
| Symbol | Design |
Design Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.85) | Revenue Per Share 0.001 | Return On Assets (0.14) | Return On Equity (0.18) |
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Design Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Design Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Design Therapeutics.
| 10/22/2024 |
| 11/21/2024 |
If you would invest 0.00 in Design Therapeutics on October 22, 2024 and sell it all today you would earn a total of 0.00 from holding Design Therapeutics or generate 0.0% return on investment in Design Therapeutics over 30 days. Design Therapeutics is related to or competes with Virax Biolabs, Kiora Pharmaceuticals, ZyVersa Therapeutics, Sonnet Biotherapeutics, Zura Bio, Phio Pharmaceuticals, and Transcode Therapeutics. Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the... More
Design Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Design Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Design Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.91 | |||
| Information Ratio | 0.0498 | |||
| Maximum Drawdown | 35.31 | |||
| Value At Risk | (8.21) | |||
| Potential Upside | 9.61 |
Design Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Design Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Design Therapeutics' standard deviation. In reality, there are many statistical measures that can use Design Therapeutics historical prices to predict the future Design Therapeutics' volatility.| Risk Adjusted Performance | 0.0586 | |||
| Jensen Alpha | 0.3532 | |||
| Total Risk Alpha | (0.28) | |||
| Sortino Ratio | 0.049 | |||
| Treynor Ratio | 1.47 |
Design Therapeutics Backtested Returns
Design Therapeutics appears to be moderately volatile, given 3 months investment horizon. Design Therapeutics secures Sharpe Ratio (or Efficiency) of 0.06, which denotes the company had a 0.06% return per unit of risk over the last 3 months. We have found thirty technical indicators for Design Therapeutics, which you can use to evaluate the volatility of the firm. Please utilize Design Therapeutics' Mean Deviation of 4.28, downside deviation of 5.91, and Coefficient Of Variation of 1510.0 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Design Therapeutics holds a performance score of 4. The firm shows a Beta (market volatility) of 0.25, which means not very significant fluctuations relative to the market. As returns on the market increase, Design Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Design Therapeutics is expected to be smaller as well. Please check Design Therapeutics' skewness, and the relationship between the value at risk and day median price , to make a quick decision on whether Design Therapeutics' price patterns will revert.
Auto-correlation | 0.09 |
Virtually no predictability
Design Therapeutics has virtually no predictability. Overlapping area represents the amount of predictability between Design Therapeutics time series from 22nd of October 2024 to 6th of November 2024 and 6th of November 2024 to 21st of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Design Therapeutics price movement. The serial correlation of 0.09 indicates that less than 9.0% of current Design Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.09 | |
| Spearman Rank Test | 0.58 | |
| Residual Average | 0.0 | |
| Price Variance | 0.36 |
Design Therapeutics lagged returns against current returns
Autocorrelation, which is Design Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Design Therapeutics' stock expected returns. We can calculate the autocorrelation of Design Therapeutics returns to help us make a trade decision. For example, suppose you find that Design Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Design Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Design Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Design Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Design Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Design Therapeutics Lagged Returns
When evaluating Design Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Design Therapeutics stock have on its future price. Design Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Design Therapeutics autocorrelation shows the relationship between Design Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Design Therapeutics.
Regressed Prices |
| Timeline |
Pair Trading with Design Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Design Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Design Stock
| 0.52 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.5 | KALV | Kalvista Pharmaceuticals | PairCorr |
| 0.49 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.49 | KTTA | Pasithea Therapeutics | PairCorr |
| 0.47 | INZY | Inozyme Pharma | PairCorr |
The ability to find closely correlated positions to Design Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Design Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Design Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Design Therapeutics to buy it.
The correlation of Design Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Design Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Design Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Design Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Design Therapeutics Correlation, Design Therapeutics Volatility and Design Therapeutics Alpha and Beta module to complement your research on Design Therapeutics. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Design Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.